Should I buy or sell Nyxoah stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NYXH shares. View NYXH analyst ratings or view top-rated stocks .

What is Nyxoah's stock price target for 2024?

6 brokers have issued 12-month target prices for Nyxoah's shares. Their NYXH share price targets range from $14.00 to $27.00. On average, they expect the company's share price to reach $20.60 in the next year. This suggests a possible upside of 115.7% from the stock's current price. View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts .

How have NYXH shares performed in 2024?

Nyxoah's stock was trading at $4.64 at the beginning of the year. Since then, NYXH stock has increased by 105.8% and is now trading at $9.55. View the best growth stocks for 2024 here .

When is Nyxoah's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our NYXH earnings forecast .

How were Nyxoah's earnings last quarter?

Nyxoah S.A. (NASDAQ:NYXH) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). The firm earned $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. Nyxoah had a negative net margin of 993.28% and a negative trailing twelve-month return on equity of 38.58%.

Nyxoah (NYXH) raised $83 million in an initial public offering (IPO) on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share.

How do I buy shares of Nyxoah?

Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NYXH

Nyxoah (NYXH) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NYXH Stock Alerts

$9.55

+0.25 (+2.69%)

(As of 04/17/2024 ET)

Compare

Today's Range: $9.11
▼
$10.03
50-Day Range: $8.90
▼
$19.50
52-Week Range: $4.00
▼
$20.00

Volume: 44,636 shs
Average Volume: 58,432 shs
Market Capitalization: $238.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.60

Get Nyxoah alerts:

Nyxoah MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 115.7% Upside
$20.60 Price Target
Short Interest: Healthy
2.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

4.4

Analyst's Opinion

Consensus Rating
Nyxoah has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Nyxoah has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
2.78% of the float of Nyxoah has been sold short.
Short Interest Ratio / Days to Cover
Nyxoah has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Nyxoah has recently decreased by 11.38%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Nyxoah does not currently pay a dividend.
Dividend Growth
Nyxoah does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NYXH.

2.3

News and Social Media Coverage

News Sentiment
Nyxoah has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Nyxoah this week, compared to 1 article on an average week.
Search Interest
5 people have searched for NYXH on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Nyxoah to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nyxoah insiders have not sold or bought any company stock.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nyxoah are expected to remain at ($1.78) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nyxoah is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nyxoah is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nyxoah has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Nyxoah Stock (NASDAQ:NYXH)

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

NYXH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NYXH Stock News Headlines

April 12, 2024 | americanbankingnews.com

Nyxoah S.A. (NASDAQ:NYXH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 11, 2024 | markets.businessinsider.com

Nyxoah Appoints Maurits Boon As Chief Medical Officer

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | globenewswire.com

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

April 11, 2024 | benzinga.com

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

March 29, 2024 | finance.yahoo.com

Information on the total number of voting rights and shares

March 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture Potential

March 25, 2024 | globenewswire.com

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth Projections

March 19, 2024 | msn.com

Nyxoah says Genio pivotal study meets primary endpoints

March 19, 2024 | globenewswire.com

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

March 7, 2024 | seekingalpha.com

Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Nyxoah Amid Record Genio Sales and Strong Growth Prospects

March 5, 2024 | investorplace.com

NYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q4 2023

March 5, 2024 | globenewswire.com

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results

March 4, 2024 | benzinga.com

Preview: Nyxoah's Earnings

February 29, 2024 | globenewswire.com

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

February 26, 2024 | msn.com

Butterfly Network, ThermoGenesis among healthcare movers

February 15, 2024 | finance.yahoo.com

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

February 15, 2024 | globenewswire.com

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

February 9, 2024 | morningstar.com

Nyxoah SA Ordinary Shares NYXH

January 17, 2024 | finance.yahoo.com

Nyxoah Announces 2024 Strategic Priorities

January 10, 2024 | msn.com

Nyxoah expects to almost double revenue in 4Q23

January 9, 2024 | finance.yahoo.com

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

December 12, 2023 | markets.businessinsider.com

Buy Rating on Nyxoah’s Genio System Amid Strong Market Potential and Positive Clinical Data

See More Headlines

Receive NYXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NYXH
CUSIP: N/A
CIK: 1857190
Web: www.nyxoah.com
Phone: 321-022-2355
Fax: 321-045-9075
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.60
High Stock Price Target: $27.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +115.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,770,000.00
Net Margins: -993.28%
Pretax Margin: -1,027.03%
Return on Equity: -38.58%
Return on Assets: -31.24%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 4.73
Quick Ratio: 4.50

Sales & Book Value

Annual Sales: $4.70 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.08 per share
Price / Book: 1.88

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.50

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Robert Taub MBA (Age 77)
Co-Founder & Chairman
Comp: $138.25k
Mr. Olivier Taelman (Age 52)
CEO & Executive Director
Comp: $683.69k
Mr. Loic Moreau (Age 43)
Chief Financial Officer
Comp: $343.41k
Mr. Bruno Onkelinx
Chief Technology Officer
Mikaela Kirkwood
Corporate Communication & Investor Relations Manager
Ms. An Moonen
General Counsel
Mr. Remi Renard
Vice President of Market & Market Access
Ms. Inge Vanwittenbergh
Global Human Resource Director
Mr. David M. DeMartino
Chief Strategy Officer
Mr. Jeyakumar Subbaroyan
Chief Clinical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NYXH Stock Analysis - Frequently Asked Questions

Should I buy or sell Nyxoah stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NYXH shares.
View NYXH analyst ratings or view top-rated stocks.
What is Nyxoah's stock price target for 2024?: 6 brokers have issued 12-month target prices for Nyxoah's shares. Their NYXH share price targets range from $14.00 to $27.00. On average, they expect the company's share price to reach $20.60 in the next year. This suggests a possible upside of 115.7% from the stock's current price.
View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts.
How have NYXH shares performed in 2024?: Nyxoah's stock was trading at $4.64 at the beginning of the year. Since then, NYXH stock has increased by 105.8% and is now trading at $9.55.
View the best growth stocks for 2024 here.
When is Nyxoah's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our NYXH earnings forecast.

How were Nyxoah's earnings last quarter?: Nyxoah S.A. (NASDAQ:NYXH) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). The firm earned $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. Nyxoah had a negative net margin of 993.28% and a negative trailing twelve-month return on equity of 38.58%.
When did Nyxoah IPO?: Nyxoah (NYXH) raised $83 million in an initial public offering (IPO) on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share.
How do I buy shares of Nyxoah?: Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NYXH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nyxoah (NYXH) Stock Price, News & Analysis

Nyxoah MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Nyxoah Stock (NASDAQ:NYXH)

NYXH Stock Price History

NYXH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NYXH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™